Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study

Xiangrui Meng, Junsheng Wang, Jin Xia, Tao Wu, Zhiquan Luo, Yonggui Hong, Ping Lu, Yanzhen Guo, Yinghua Ji, Min Zhang, Liuzhong Yang, Peng Cheng, Wenchang Liang, Zhengzheng Shan, Yue Zhou, Mingyue Wang, Taiying Lu, Min Seok Song, Hong Zong, Lijie Song, Wenkang Wang, Lulu Guan, Yanke Li, Jianxiang Xing, Siyuan Xing, Han Wu, Jingwen Chu, Xi Luo, Lu Yao, Dao Xin, Aijia Li, Bing‐Hua Jiang, Shenglei Li, Guozhong Jiang, Qingxia Fan, Feng Zhao, Rongrong Zheng, Wenqing Zhu, Zhiguo Hou, Yun Jia, Feng Wang